Abstract:Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30–40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not only decreased a quality of life, and cognitive, behavioral, and personal disorders, but also an increased risk of death, i.e., in the mechanism of sudden unexpected death in epilepsy patients (SUDEP). The main goals of epilepsy treatment include three basic issues: achieving the best possible seizure control, avoiding the undesired effects of treatment, and maintaining/improving the quality of patients' lives. Therefore, numerous attempts are made to offer alternative treatments for drug-resistant seizures, an example of which is the ketogenic diet. It is a long-known but rarely used dietary therapy for intractable seizures. One of the reasons for this is the unpalatability of the classic ketogenic diet, which reduces patient compliance and adherence rates. However, its antiseizure effects are often considered to be worth the effort. Until recently, the diet was considered the last-resort treatment. Currently, it is believed that a ketogenic diet should be used much earlier in patients with well-defined indications. In correctly qualified patients, seizure activity may be reduced by over 90% or even abolished for long periods after the diet is stopped. A ketogenic diet can be used in all age groups, although most of the available literature addresses pediatric epilepsy. In this article, we focus on the mechanisms of action, effectiveness, and adverse effects of different variants of the ketogenic diet, including its classic version, a medium-chain triglyceride diet, a modified Atkins diet, and a low glycemic index treatment.
What problem does this paper attempt to address?
The paper primarily discusses the application of the ketogenic diet (KD) in the treatment of epilepsy, particularly its role in patients with drug-resistant epilepsy. Despite the development of third-generation antiepileptic drugs (AEDs), there are still 30%-40% of epilepsy patients who do not respond to medication. These patients face a decline in quality of life, cognitive and behavioral disorders, personal health issues, and an increased risk of sudden unexpected death. Therefore, it is necessary to seek alternative therapies, among which the ketogenic diet, as a long-standing but less commonly used dietary therapy, has attracted attention.
The paper outlines the basic principles of the ketogenic diet, which induces ketone body production through a diet pattern of extremely low carbohydrates, high fat, and moderate protein, thereby potentially controlling epileptic seizures. Different variants of the ketogenic diet, including the classic ketogenic diet (cKD), medium-chain triglyceride (MCT) diet, modified Atkins diet (MAD), and low glycemic index treatment (LGIT), have been designed to improve patient compliance and satisfaction, and to reduce adverse reactions.
The paper discusses in detail the application of the ketogenic diet across different age groups, with a particular emphasis on its effectiveness in children and adolescents, especially in specific types of drug-resistant epilepsy such as infantile spasms, Ohtahara syndrome, and early infantile epileptic encephalopathy with migrating focal seizures. For adult patients, the ketogenic diet has also been proven effective in certain cases, especially for those who are unresponsive to medication or experience severe side effects.
Furthermore, the paper explores the potential mechanisms of action of the ketogenic diet, including the regulation of neuronal excitability by ketone bodies, changes in neurotransmitter levels, activation of potassium channels, improvement of mitochondrial function, epigenetic modifications, and reshaping of the gut microbiome.
In conclusion, the paper aims to highlight the ketogenic diet as a viable and effective alternative method for the treatment of epilepsy, particularly in patients with drug-resistant epilepsy, and calls for its earlier application in suitable patient groups. At the same time, the paper also mentions the challenges of the ketogenic diet, such as patient compliance, management of adverse reactions, and the assessment of long-term therapeutic effects.